Bottom line
RXL vs SWHFX: the short answer
RXL (ProShares Ultra Health Care) and SWHFX (Schwab Health Care Fund) share a meaningful slice of their top holdings — about 68% by weight.
SWHFX is cheaper at 0.8% vs 0.95% — a difference of $15 a year per $10,000 invested.
Over five years, RXL returned +7.2% a year vs +6.5% for SWHFX.
Updated Nov 19, 2026
RXL vs SWHFX side by side
| RXL | SWHFX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | ProShares | Schwab |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.95% | 0.8% |
| Annual cost per $10k | $95 | $80 |
| 10-yr cost on $10k (prospectus) | $1,305 | $990 |
| Max front load | None | — |
| 12b-1 fee | — | 0% |
| 1-yr return | +19.7% | +15.9% |
| 5-yr return (annualized) | +7.2% | +6.5% |
| 10-yr return (annualized) | +12.6% | +8.1% |
| Best quarter | +29.7% | +15.3% |
| Worst quarter | −28.9% | −12.1% |
| Net assets (fund) | $72.1M | $642.3M |
| Number of holdings | 70 | 80 |
| Portfolio turnover | 4% | 41% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | RXL | SWHFX | Difference |
|---|---|---|---|
| 2025 | +19.7% | +15.9% | +3.8% |
| 2024 | −2.7% | +0.1% | −2.8% |
| 2023 | −3.2% | +0.7% | −3.8% |
| 2022 | −15.1% | −4.7% | −10.5% |
| 2021 | +47.8% | +23.3% | +24.5% |
| 2020 | +19.2% | +12.9% | +6.4% |
| 2019 | +38.9% | +17.6% | +21.3% |
| 2018 | +5.4% | +4.0% | +1.4% |
| 2017 | +46.0% | +20.2% | +25.8% |
| 2016 | −8.9% | −4.4% | −4.6% |
Source: Fund prospectus bar charts
Holdings overlap
17 of RXL's top 25 holdings also appear in SWHFX's top 25.
| Holding | RXL | SWHFX |
|---|---|---|
| Eli Lilly & Co. | 12.67% | 13.92% |
| Johnson & Johnson | 7.86% | 6.94% |
| AbbVie, Inc. | 5.57% | 5.81% |
| UnitedHealth Group, Inc. | 4.98% | 4.74% |
| Merck & Co., Inc. | 4.26% | 4.98% |
| Thermo Fisher Scientific, Inc. | 2.68% | 2.16% |
| Amgen, Inc. | 2.62% | 2.58% |
| Gilead Sciences, Inc. | 2.41% | 3.24% |
| Abbott Laboratories | 2.15% | 1.60% |
| Bristol-Myers Squibb Co. | 1.68% | 2.44% |
| Danaher Corp. | 1.66% | 1.47% |
| Vertex Pharmaceuticals, Inc. | 1.64% | 1.89% |
| Stryker Corp. | 1.52% | 2.11% |
| Medtronic plc | 1.37% | 2.29% |
| Elevance Health, Inc. | 1.26% | 1.45% |
Source: SEC Form N-PORT
RXL top 10
- Eli Lilly & Co. — 12.67%
- ProShares GENIUS Money Market ETF — 11.81%
- Johnson & Johnson — 7.86%
- AbbVie, Inc. — 5.57%
- UnitedHealth Group, Inc. — 4.98%
- Merck & Co., Inc. — 4.26%
- Repurchase Agreement — 2.91%
- Thermo Fisher Scientific, Inc. — 2.68%
- Amgen, Inc. — 2.62%
- Gilead Sciences, Inc. — 2.41%
SWHFX top 10
- Eli Lilly & Co — 13.92%
- Johnson & Johnson — 6.94%
- AbbVie Inc — 5.81%
- Merck & Co Inc — 4.98%
- UnitedHealth Group Inc — 4.74%
- Gilead Sciences Inc — 3.24%
- Novartis AG — 2.92%
- Amgen Inc — 2.58%
- Bristol-Myers Squibb Co — 2.44%
- Medtronic PLC — 2.29%
FAQ
What is the difference between RXL and SWHFX?
Which is cheaper, RXL or SWHFX?
Should I own both RXL and SWHFX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.